These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 16336946)

  • 41. Synthetic cannabinoid presentations decline following ban.
    Christie G; MacFarlane V
    Drug Alcohol Rev; 2016 Mar; 35(2):E3-4. PubMed ID: 26492870
    [No Abstract]   [Full Text] [Related]  

  • 42. Evaluating the Safety of Cannabinoid-Based Medicines for Older Adults.
    Fick DM
    JAMA Netw Open; 2021 Feb; 4(2):e2035952. PubMed ID: 33528548
    [No Abstract]   [Full Text] [Related]  

  • 43. Cannabinoid testing.
    Sahni V
    Br Dent J; 2021 Sep; 231(5):267. PubMed ID: 34508185
    [No Abstract]   [Full Text] [Related]  

  • 44. Withdrawal of Expression of Concern.
    Child Dev; 2014 May; 85(3):1321. PubMed ID: 29168572
    [No Abstract]   [Full Text] [Related]  

  • 45. Chemistry and Pharmacology of Delta-8-Tetrahydrocannabinol.
    Abdel-Kader MS; Radwan MM; Metwaly AM; Eissa IH; Hazekamp A; ElSohly MA
    Molecules; 2024 Mar; 29(6):. PubMed ID: 38542886
    [No Abstract]   [Full Text] [Related]  

  • 46. Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine.
    Lichtman AH; Fisher J; Martin BR
    Pharmacol Biochem Behav; 2001; 69(1-2):181-8. PubMed ID: 11420084
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice.
    Anggadiredja K; Yamaguchi T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T
    Brain Res; 2003 Mar; 966(1):47-53. PubMed ID: 12646307
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
    Lichtman AH; Sheikh SM; Loh HH; Martin BR
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discriminative stimulus effects of the cannabinoid antagonist, SR 141716A, in delta -sup-9-tetrahydrocannabinol-treated rhesus monkeys.
    McMahon LR; France CP
    Exp Clin Psychopharmacol; 2003 Nov; 11(4):286-93. PubMed ID: 14599262
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs.
    Lichtman AH; Wiley JL; LaVecchia KL; Neviaser ST; Arthur DB; Wilson DM; Martin BR
    Eur J Pharmacol; 1998 Sep; 357(2-3):139-48. PubMed ID: 9797029
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal: a quasi abstinence approach.
    Anggadiredja K; Yamaguchi T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T
    Brain Res; 2005 Dec; 1066(1-2):201-5. PubMed ID: 16336946
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.